Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial
Year: 2017
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Importance: Type 1 diabetes requires major lifestyle changes and carries increased morbidity and mortality. Prevention or delay of diabetes would have major clinical effect. Objective: To determine whether oral insulin delays onset of type 1 diabetes in autoantibody-positive relatives of patients with type 1 diabetes. Design, Setting, and Participants: Between March 2, 2007, and December 21, 2015, relatives with at least 2 autoantibodies, including insulin autoantibodies and normal glucose tolerance, were enrolled in Canada, the United States, Australia, New Zealand, the United Kingdom, Italy, Sweden, Finland, and Germany. The main study group (n = 389) had first-phase insulin release on an intravenous glucose tolerance test that was higher than the threshold. The 55 patients in the secondary stratum 1 had an identical antibody profile as the main study group except they had first-phase insulin release that was lower than the threshold. Secondary strata 2 (n = 114) and strata 3 (n = 3) had different autoantibody profiles and first-phase insulin release threshold combinations. Follow-up continued through December 31, 2016. Interventions: Randomization to receive 7.5 mg/d of oral insulin (n = 283) or placebo (n = 277), including participants in the main study group who received oral insulin (n = 203) or placebo (n = 186). Main Outcome and Measures: The primary outcome was time to diabetes in the main study group. Significance was based on a 1-sided threshold of .05, and 1-sided 95% CIs are reported. Results: Of a total of 560 randomized participants (median enrollment age, 8.2 years; interquartile range [IQR], 5.7-12.1 years; 170 boys [60%]; 90.7% white non-Hispanic; 57.6% with a sibling with type 1 diabetes), 550 completed the trial including 389 participants (median age, 8.4 years; 245 boys [63%]), 382 (96%) in the main study group. During a median follow-up of 2.7 years (IQR, 1.5-4.6 years) in the main study group, diabetes was diagnosed in 58 participants (28.5%) in the oral insulin group and 62 (33%) in the placebo group. Time to diabetes was not significantly different between the 2 groups (hazard ratio [HR], 0.87; 95% CI, 0-1.2; P = .21). In secondary stratum 1 (n = 55), diabetes was diagnosed in 13 participants (48.1%) in the oral insulin group and in 19 participants (70.3%) in the placebo group. The time to diabetes was significantly longer with oral insulin (HR, 0.45; 95% CI, 0-0.82; P = .006). The HR for time to diabetes for the between-group comparisons for the 116 participants in the other secondary stratum was 1.03 (95% CI, 0-2.11; P = .53) and for the entire cohort of 560 participants was 0.83 (95% CI, 0-1.07; P = .11), which were not significantly different. The most common adverse event was infection (n = 254), with 134 events in the oral insulin group and 120 events in the placebo group, but no significant study-related adverse events occurred. Conclusions and Relevance: Among autoantibody-positive relatives of patients with type 1 diabetes, oral insulin at a dose of 7.5 mg/d, compared with placebo, did not delay or prevent the development of type 1 diabetes over 2.7 years. These findings do not support oral insulin as used in this study for diabetes prevention. Trial Registration: clinicaltrials.gov Identifier: NCT00419562.
Source: JAMA
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: bronze
Funders: Eli Lilly and Company, Yale University, Children's Hospital Los Angeles, Vanderbilt University, University of Miami, University of Pennsylvania, Emory University, George Washington University, Wake Forest University, Harvard University, University of Minnesota, Cleveland Clinic, Baylor University, North Carolina State University, Helsingin Yliopisto, University of Washington, Joslin Diabetes Center, University of Pittsburgh, Georgetown University, University of South Florida, Children's Mercy Hospital, Children's National Hospital, King's College London, University of Bristol, Universiteit Leiden, Lunds Universitet, University of Toronto, Leids Universitair Medisch Centrum, Turun Yliopisto, National Institutes of Health, University of California, Los Angeles, University of California, San Francisco, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Child Health and Human Development, National Center for Research Resources, National Center for Advancing Translational Sciences, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: G1132206153, Los Angeles Basin Clinical and Translational Science Institute, UF Clinical and Translational Science Award, Type 1 Diabetes TrialNet: Clinical Centers, TrialNet: University of Florida Clinical Center and Network, Type 1 Diabetes TrialNet at Indiana University Clinical Center, Type 1 Diabetes-A Proposal for Prevention & Intervention, CLINICAL AFFILIATE OF THE TYPE 1 DIABETES TRIALNET, Preservation of Beta Cells by Glutamate Decarboxylase, Chicagoland Diabetes TrialNet Clinical Center, GCRC-General Clinical Research Center, TrialNet: University of Florida Clinical Center and Network, Indiana Clinical and Translational Sciences Institute, Type 1 Diabetes Trialnet: Operations Coord. Center, Stanford Center for Clinical and Translational Education and Research (SCCTER)UL1, Immunotherapy for Type 1 Diabetes, Type 1 Diabetes-A Proposal for Prevention & Intervention, Diabetes Type 1 TrialNet: Clinical Centers, Continuation of UCSF as a Clinical Center for TrialNet, University of Pittsburgh Clinical and Translational Science Institute, Diabetes TrialNet, Type 1 Diabetes TrialNet Clinical Centers - Kansas City, Prediction and Prevention of Type 1 Diabetes (TrialNet), Northwest Clinical Center for Type 1 Diabetes - TrialNet, Type 1 Diabetes TrialNet: Clinical Center at Columbia University, Type 1 Diabetes TrialNet: Clinical Center at Berrie Center, Columbia University, North and Central Texas Clinical and Translational Science Initiative (UL1), Indiana Clinical and Translational Science Institute (UL1), Type 1 Diabetes TrialNet: Toronto Clinical Center, NIDDK Type 1 Diabetes TrialNet Data Coordinating Center, TrialNet at Stanford University, Vanderbilt University: Clinical Center Application, Type 1 Diabetes TrialNet, Type 1 Diabetes TrialNet: Toronto Clinical Centre, The Vanderbilt Institute for Clinical and Translational Research (VICTR) UL1, USF TrialNet Clinical Center, Type 1 Diabetes TrialNet: Clinical Centers (U01), Data Coordinating Center for Type 1 Diabetes TrialNet (UC4)USF: TrialNet UC4-3, Type 1 Diabetes TrialNet: Support Facilities, Type 1 diabetes TrialNet Center at Yale University, Yale University Clinical and Translational Science Award Program, NIDDK Type 1 Diabetes TrialNet Data Coordinating Center, TrialNet: Diabetes Type 1 Prevention, Type 1 Diabetes TrialNet at Indiana University Clinical Center, An Atlanta TrialNet Center: Building a Pathway to 70 Clinical Trial Subjects per Year, TrialNet: Diabetes Type 1 Prevention Trial, Type 1 Diabetes TrialNet Clinical Network Hub, Southern California Clinical and Translational Science Institute, Colorado Clinical and Translational Science Institute (UL1)
OpenAlex ID: W2769332703
